This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs
by Zacks Equity Research
Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.
Is Bausch Health (BHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
All You Need to Know About Bausch (BHC) Rating Upgrade to Buy
by Zacks Equity Research
Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?
by Zacks Equity Research
Aerie (AERI) gains momentum on the back of the FDA approval of its second drug, Rocklatan.
Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
by Zacks Equity Research
Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.
Why Is Bausch (BHC) Up 8.3% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Bausch Health Companies (BHC) a Great Stock for Value Investors?
by Zacks Equity Research
Is Bausch Health Companies (BHC) a great pick from the value investor's perspective right now? Read on to know more.
Aerie (AERI) Q4 Earnings Miss, Rhopressa Gains Traction
by Zacks Equity Research
Aerie (AERI) reports wider-than-expected Q4 loss. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.
Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 19.32% and 1.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
Investors are looking forward to Salix and Bausch+Lomb's performance, and other pipeline updates when Bausch (BHC) reports Q4 results on Feb 20.
Earnings Preview: Bausch Health (BHC) Q4 Earnings Expected to Decline
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch (BHC) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for February 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.
Is Bausch Health (BHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Has Bausch Health Cos (BHC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BHC) Outperforming Other Medical Stocks This Year?
Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.
Why Bausch (BHC) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bausch Health (BHC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed at $22.34 in the latest trading session, marking a +0.4% move from the prior day.
Is Bausch Health (BHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed the most recent trading day at $22.68, moving +1.43% from the previous trading session.
Implied Volatility Surging for Bausch (BHC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bausch (BHC) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: inTest, Progressive, BioTelemetry, Bausch Health and Steelcase
by Zacks Equity Research
The Zacks Analyst Blog Highlights: inTest, Progressive, BioTelemetry, Bausch Health and Steelcase
Bull or Bear: Your Investment Strategy for 2019
by Sejuti Banerjea
Whether you're a bull or a bear, it may be a good idea to go defensive about now.